Orion Sight to is first quarter, all our the our to Second better this Thank management thank key ever before by several our the review reach and I'd technology. since first directors. and treat afternoon. advancing board our and you blind like than developments of I during of call With and to the joining Lisa, expanding team Argus for solution believe you changes key positioned
to welcoming John by Tom Second team him of am transition IPO. delivering a many executive first successful with seasoned once to begin his record him helped of again. moment thank I'd integral to life his I Tom a John I a ensure wish call has Miller graciously will He experience was contributions track team a Sight's me be as to for Blake leadership that Sight the John the well. also and company's take working to company. we the member like pleased that joined Second with is to Let broad he sciences industry management and CFO. a results. and financial and seamless valued
to expanding to you market a know, announced the bring the of as the working with contributed of Bob enjoyed Bob options pioneer officer As Directors I our for as in industry and from advance extensively company. technologies the an Greenberg Second of resignation Board Dr. Robert Sight's in worldwide. is and and them breakthrough we to blind. April,
years and sincerely announced as appreciate Second insights we technical his Also, contributions well. previously wish Sight extensive of Gregg team, his March, appointed was of Williams the leadership clinical and and Board. the has benefited industry in the On from entire him knowledge. Chairman behalf over
of to to externals the Gregg's by team year, further strategy key to Argus Second to investment the development guidance technology, of to enrollment vision he week. the appreciate and study his of order achieve adoption implementation funding business As continuing continued to regulatory our regulatory in investment Argus approvals, our a this valuable has million Argus Excellence of of clinical board Orion last leadership provided confidence his population and and II. milestones data future we better seeking pursuing demonstrated Centers breakthrough for the feasibility Sight next-generation strategy commercial of and safety and the member, provide drive and II our including this approvals $X and with to completing support of patients II, treat efficacy treatable gather in completing development expand as
first we turn year ahead. a will now discussion be to believe a and quarter me our the let what during of business So since significant and
XXth at a our or Let's very year, implemented Ronald of we're human start UCLA. with UCLA progress we exciting January Reagan Center subject Orion. the first this On our with making Medical
have as study. been activated of successfully part feasibility since We our
is feasibility reminder, been quarter. we Orion later expected Medicine five-subject report College a not yet has study now are of a four to but UCLA been The surgery this Baylor the of occur very implanted. conducting in pleased five at study have scheduled to Houston. and that I'm subjects fifth the As
subjects two first sessions have been well. have the The and activated gone stimulation
may You phased stimulated testing each during first electrodes the XX the individually the being with that phase. recall is of
the the on progressing of results testing phase spot process expected. underway two perception The light determining spatial of next The two each actually in with subject's all consistent as subjects process spots includes is phase a the subjects of see have mapping appear next electrodes. testing The first and where or camera. spatial the field. mapping of sixty visual and The from the of produces involves electrode subject's which light first is a turning
other It's pleased my has The with serious has have stimulation our events. been I first To mapping be been there no to and scanning important am results quite spatial skills. expectations. can on and that and note subject's adverse testing locate is clear, and turned camera also light and head early he practicing visual exceeded
stimulation in Looking four future. forward, and near activate testing for three begin subjects we the will and
signals that testing you updating creating I progress the on stimulate into forward begin algorithms also camera. calls. the with patterns patients vision. real-time look during The input electrodes converted will two our be in video will to first by future We video our artificial from
part our a the program, initial completed Orion is Last As meeting and to step. at week, requested breakthrough the of we next the review for priority submission by FDA. device eligible the FDA
to path Our and can FDA sufficiently, goal is Orion year clinical we this for regulatory with so regarding that the investors update the through advance the discussions later to commercialization.
now turn Let's to Argus business. the
with completed implants During have North QX in Argus QX, we ten begun momentum. II America and substantial
team early XXX U.S. and March outreach over entire patients, US grown Our gain XXX of strategy the our end covering Centers now efforts, to the and database traction the to at of in third full US. quarter. place has a Due have clinician-qualified XX patient Excellence to patient we our in the in up from continues
a expect source qualified We the Argus for individuals database growing to implant. of be an
during the quarter of Care In and additional came the fact, from Ontario Ontario discussed In for eleven Technology and based currently of Committee. Health for scheduled year. previously an Health in individuals database Long-Term America recommendations approved the Advisory Ministry II four this implanted Canada, surgery are Argus the the first North the funding later on
of US With Excellence expect center the reimbursement in planning in under our strategy in the is first scaling growth our evaluate we we growing Centers next of number to and expanded America. Argus II US program North Toronto reimbursement and Our to patient patient continued XX implants in shortly. our expect Canada, two the in days, nicely, implant and the database patients
implants the the quarter XXXX. Europe, completed East, Middle to and Asia, we during first of six Turning
team currently in With discussed region our business As quite refining progress many is that Innovation Program. overall France, to American different than the we good making and the potential and perform additional commercial in the to approved with continuing markets secure variability three part implants the this as have in reimbursement sites markets. said, of In for market. strategy complex Forfait is more past, North much the
were a accepted number program to France. expand or in on in national are CtE NHS that funding a was French the through accepted the in first are data and authority collecting a innovation mid-year. the After a reimbursement, the England's we implants Commissioning innovation longer-term performing allowing France report also XX planning Evaluation centers accelerate ultimately positive patients, were Program transition program of outcome We us the to now the believe will reviewing We the program promising we introduction expected, reminder, similar launched in early to under supporting first of the optimistic company be by As the to Forfait implants XXXX. reimbursement data to slower have progressing decision. reimbursement also which France. program to not final and Innovation in is than This but submit begin will program to to the and XXXX the is or medical late we support until
XXXX, early with XXXX. implants had with have Before entered completing our discussing patient as in markets highlight five strategy four well. XX new we've since markets implants, I'd distributor we've success the great of like our a impressive revamping completed since markets more late some outcomes had we've R&D, or the In in to total Overall, three each. results we
on the front, testing portion Again, Turning stimulation include the that on a so to We which II. the and on population ready, RP late new reach a testing developing stimulation experience to VPU We make Argus vision in this current a generation first programs are users regulatory track our eyewear, and requesting treatable platform. usefulness next is and/or externals work by the been XXXX. our supplement technology are process. Argus submissions would the provided to completed we the our the programs, will FDA only new the for during patient patients. we that can anticipated be label in adjustable advanced to technology hopeful also remain better Argus of to we we the improving are but of improve with a summer expand and externals, we meaningful focused externals submitted US launch our our more has an that difference. that programs newer HDE patients market capable next-generation could the various of On these R&D, quarter Once improve our change the not to to continue stimulation camera, advanced able vision for in will remain expand quality design complete whom
in We a delay and appropriate. note, and the focus with With are vision the to On to optimistic about market. a as made John our remain we'll first call in would better related you like the RP quarter to submission desire label now to trial over concerning our John? in that, moving forward discussions update US have on our FDA ability to US I Germany decision review substantially we the results. expand the our with larger to financial given turn our
